Virpax Pharmaceuticals Stock Net Income
| VRPX Stock | USD 0.01 0.00 0.00% |
As of the 8th of February, Virpax Pharmaceuticals has the Variance of 56952.48, coefficient of variation of 751.12, and Risk Adjusted Performance of 0.1172. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Virpax Pharmaceuticals, as well as the relationship between them.
Virpax Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Virpax Pharmaceuticals' valuation are provided below:Virpax Pharmaceuticals does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Virpax |
Virpax Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Virpax Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Virpax Pharmaceuticals.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Virpax Pharmaceuticals on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Virpax Pharmaceuticals or generate 0.0% return on investment in Virpax Pharmaceuticals over 90 days. Virpax Pharmaceuticals is related to or competes with P3 Health, Dermata Therapeutics, Revelation Biosciences, Aclarion, Akari Therapeutics, and Purple Biotech. Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and dru... More
Virpax Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Virpax Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Virpax Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1328 | |||
| Maximum Drawdown | 1989.0 |
Virpax Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Virpax Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Virpax Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Virpax Pharmaceuticals historical prices to predict the future Virpax Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1172 | |||
| Jensen Alpha | 30.75 | |||
| Total Risk Alpha | 8.17 | |||
| Treynor Ratio | 2.5 |
Virpax Pharmaceuticals February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1172 | |||
| Market Risk Adjusted Performance | 2.51 | |||
| Mean Deviation | 67.05 | |||
| Coefficient Of Variation | 751.12 | |||
| Standard Deviation | 238.65 | |||
| Variance | 56952.48 | |||
| Information Ratio | 0.1328 | |||
| Jensen Alpha | 30.75 | |||
| Total Risk Alpha | 8.17 | |||
| Treynor Ratio | 2.5 | |||
| Maximum Drawdown | 1989.0 | |||
| Skewness | 7.65 | |||
| Kurtosis | 60.3 |
Virpax Pharmaceuticals Backtested Returns
Virpax Pharmaceuticals is out of control given 3 months investment horizon. Virpax Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.14, which indicates the firm had a 0.14 % return per unit of risk over the last 3 months. We were able to interpolate data for sixteen different technical indicators, which can help you to evaluate if expected returns of 19.31% are justified by taking the suggested risk. Use Virpax Pharmaceuticals Variance of 56952.48, coefficient of variation of 751.12, and Risk Adjusted Performance of 0.1172 to evaluate company specific risk that cannot be diversified away. Virpax Pharmaceuticals holds a performance score of 11 on a scale of zero to a hundred. The entity has a beta of 12.69, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Virpax Pharmaceuticals will likely underperform. Use Virpax Pharmaceuticals standard deviation and the relationship between the treynor ratio and day typical price , to analyze future returns on Virpax Pharmaceuticals.
Auto-correlation | 0.00 |
No correlation between past and present
Virpax Pharmaceuticals has no correlation between past and present. Overlapping area represents the amount of predictability between Virpax Pharmaceuticals time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Virpax Pharmaceuticals price movement. The serial correlation of 0.0 indicates that just 0.0% of current Virpax Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.65 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Virpax Pharmaceuticals reported net income of (12.07 Billion). This is 3635.85% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is significantly higher than that of the company.
Virpax Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Virpax Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Virpax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Virpax Pharmaceuticals by comparing valuation metrics of similar companies.Virpax Pharmaceuticals is currently under evaluation in net income category among its peers.
Virpax Fundamentals
| Return On Equity | -23.65 | |||
| Return On Asset | -1.35 | |||
| Current Valuation | (1.21 M) | |||
| Shares Outstanding | 1.24 M | |||
| Shares Owned By Insiders | 0.96 % | |||
| Shares Owned By Institutions | 0.41 % | |||
| Number Of Shares Shorted | 577.07 K | |||
| Price To Book | 0.48 X | |||
| EBITDA | (12.08 B) | |||
| Net Income | (12.07 B) | |||
| Cash And Equivalents | 26.06 M | |||
| Cash Per Share | 2.22 X | |||
| Total Debt | 2.47 B | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 11.84 X | |||
| Book Value Per Share | (1.53) X | |||
| Cash Flow From Operations | (16.71 B) | |||
| Short Ratio | 0.04 X | |||
| Earnings Per Share | (71.00) X | |||
| Target Price | 3.0 | |||
| Beta | 1.42 | |||
| Market Capitalization | 831.85 K | |||
| Total Asset | 1.56 B | |||
| Retained Earnings | (71.61 B) | |||
| Working Capital | (913.76 K) | |||
| Net Asset | 1.56 B |
About Virpax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Virpax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virpax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virpax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virpax Pink Sheet Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.